Put Options

9 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2022

Oct 25, 2022

SELL
$7.48 - $15.24 $2,244 - $4,572
-300 Reduced 37.5%
500 $22,000
Q2 2022

Aug 04, 2022

BUY
$13.18 - $19.41 $1,318 - $1,941
100 Added 14.29%
800 $42,000
Q1 2022

Apr 14, 2022

SELL
$14.73 - $35.25 $297,546 - $712,050
-20,200 Reduced 96.65%
700 $35,000
Q4 2021

Jan 18, 2022

BUY
$33.72 - $48.22 $229,296 - $327,896
6,800 Added 48.23%
20,900 $132,000
Q3 2021

Oct 26, 2021

SELL
$49.26 - $74.5 $1.13 Million - $1.71 Million
-22,900 Reduced 61.89%
14,100 $222,000
Q2 2021

Jul 19, 2021

BUY
$56.91 - $127.53 $1.13 Million - $2.54 Million
19,900 Added 116.37%
37,000 $479,000
Q1 2021

Apr 26, 2021

SELL
$79.79 - $126.29 $2.24 Million - $3.55 Million
-28,100 Reduced 62.17%
17,100 $319,000
Q4 2020

Jan 21, 2021

BUY
$46.76 - $136.27 $331,996 - $967,517
7,100 Added 18.64%
45,200 $1.18 Million
Q3 2020

Oct 27, 2020

BUY
$43.8 - $77.2 $1.67 Million - $2.94 Million
38,100 New
38,100 $722,000

Others Institutions Holding CVAC

About CureVac N.V.


  • Ticker CVAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,467,008
  • Market Cap $514M
  • Description
  • CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...
More about CVAC
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.